OBJECTIVES: We estimated human papillomavirus (HPV) vaccine series completion and examined predictors of completion among adolescents and young adults in a large family planning network. METHODS: Our retrospective cohort study of vaccine completion within 12 months and time to completion used electronic health record data from 119 Planned Parenthood health centers in 11 US states for 9648 patients who initiated HPV vaccination between January 2011 and January 2013. RESULTS: Among vaccine initiators, 29% completed the series within 12 months. Patients who were male, younger than 22 years, or non-Hispanic Black or who had public insurance were less likely to complete within 12 months and completed more slowly than their counterparts. Gender appeared to modify the effect of public versus private insurance on completion (adjusted hazard ratio = 0.76 for women and 0.95 for men; relative excess risk due to interaction = 0.41; 95% confidence interval = 0.09, 0.73). CONCLUSIONS: Completion was low yet similar to previous studies conducted in safety net settings.
OBJECTIVES: We estimated human papillomavirus (HPV) vaccine series completion and examined predictors of completion among adolescents and young adults in a large family planning network. METHODS: Our retrospective cohort study of vaccine completion within 12 months and time to completion used electronic health record data from 119 Planned Parenthood health centers in 11 US states for 9648 patients who initiated HPV vaccination between January 2011 and January 2013. RESULTS: Among vaccine initiators, 29% completed the series within 12 months. Patients who were male, younger than 22 years, or non-Hispanic Black or who had public insurance were less likely to complete within 12 months and completed more slowly than their counterparts. Gender appeared to modify the effect of public versus private insurance on completion (adjusted hazard ratio = 0.76 for women and 0.95 for men; relative excess risk due to interaction = 0.41; 95% confidence interval = 0.09, 0.73). CONCLUSIONS: Completion was low yet similar to previous studies conducted in safety net settings.
Authors: Jason D Wright; Shravya Govindappagari; Neha Pawar; Kirsten Cleary; William M Burke; Patricia C Devine; Yu-Shiang Lu; Wei-Yann Tsai; Sharyn N Lewin; Thomas J Herzog Journal: Obstet Gynecol Date: 2012-10 Impact factor: 7.661
Authors: Robine Donken; Mirjam J Knol; Johannes A Bogaards; Fiona R M van der Klis; Chris J L M Meijer; Hester E de Melker Journal: J Infect Date: 2015-02-21 Impact factor: 6.072
Authors: Lea E Widdice; David I Bernstein; Anthony C Leonard; Keith A Marsolo; Jessica A Kahn Journal: Pediatrics Date: 2010-12-13 Impact factor: 7.124
Authors: Sharon J M Kessels; Helen S Marshall; Maureen Watson; Annette J Braunack-Mayer; Rob Reuzel; Rebecca L Tooher Journal: Vaccine Date: 2012-04-03 Impact factor: 3.641
Authors: Muhammad Amith; Trevor Cohen; Rachel Cunningham; Lara S Savas; Nina Smith; Paula Cuccaro; Efrat Gabay; Julie Boom; Roger Schvaneveldt; Cui Tao Journal: Cancer Control Date: 2020 Jan-Dec Impact factor: 3.302